• Add two KOLs: Dr Kris Kowdley and Dr Nadege Gunn • Builds on existing MASH/MASLD capabilities at 23 sites globally DURHAM N.C., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Velocity Clinical Research (“Velocity”), the leading multi-specialty clinical sites business, announced it has acquired Impact Research Institute (Waco, TX) and the clinical trials unit of Liver Institute Northwest (Seattle, WA), aggressively expanding its capabilities in liver disease research, including MASH (metabolic dysfunction-associated steatohepatitis) and MASLD (metabolic dysfunction-associated steatotic liver disease).

•添加两个KOLs:Kris Kowdley博士和Nadege Gunn博士•建立在全球23个站点现有的MASH/MASLD功能的基础上-达勒姆N.C.，2023年10月25日（GLOBE NEWSWIRE）-速度临床研究（“Velocity”），领先的多专业临床网站业务，宣布收购了Impact研究所（Waco，TX）和西北肝脏研究所（西雅图，华盛顿州）的临床试验单位，积极扩大其肝病研究能力，包括MASH（代谢功能障碍相关性脂肪性肝炎）和MASLD（代谢功能障碍）相关的脂肪性肝病）。

According to the NASH education program, MASLD, prevalent in Western societies, is primarily driven by the rising cases of obesity and type 2 diabetes. The prevalence of MASH is projected to surge by 63% from 2015 to 2030, making it a significant health concern, and it is anticipated to be the primary reason for liver transplants in the United States from 2020 to 2025.

根据NASH教育计划，MASLD在西方社会盛行，主要是由于肥胖和2型糖尿病病例的增加。从2015年到2030年，MASH的患病率预计将激增63%，使其成为一个重大的健康问题，预计将成为2020年至2025年美国肝移植的主要原因。

Despite its growing impact, there is currently no FDA-approved treatment available for this condition. Velocity is a major player in this space with 23 sites capable of performing MASH/MASLD studies globally. With the two recent site acquisitions, Velocity adds two internationally renowned researchers and key opinion leaders (KOL) in liver disease research as principal investigators, Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, and Nadege Gunn, MD, CPI, who join Roland Kuchta, MD, in Germany.

尽管其影响越来越大，但目前还没有FDA批准的治疗方法可用于治疗这种疾病。Velocity是这个领域的主要参与者，有23个站点能够在全球范围内进行MASH/MASLD研究。随着最近两次现场收购，Velocity增加了两位国际知名研究人员和肝病研究的主要意见领袖（KOL）作为主要研究人员，Kris Kowdley，医学博士，AGAF，FAASLD，FACP，FACG和Nadege Gunn，医学博士，CPI，谁加入德国的Roland Kuchta医学博士。

Dr. Kris Kowdley received his medical degree from Mount Sinai School of Medicine, completed his residency at Oregon Health Science University and fellowship in gastroenterology and hepatology at Tufts University School of Medicine. Dr. Kowdley is internationally recognized as a clinician, educator, and researcher in the area of he.

Kris Kowdley博士从西奈山医学院获得医学学位，在俄勒冈健康科学大学完成住院治疗，并在塔夫茨大学医学院获得胃肠病学和肝病学奖学金。Kowdley博士在he领域被国际公认为临床医生，教育者和研究员。